Production (Stage)
Gain Therapeutics, Inc.
GANX
$1.73
-$0.07-3.89%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -100.00% | -100.00% | -100.00% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -100.00% | -100.00% | -100.00% |
| Cost of Revenue | -7.26% | -7.38% | 155.11% | 93.21% | 44.92% |
| Gross Profit | 7.26% | 7.01% | -157.75% | -94.72% | -47.27% |
| SG&A Expenses | -3.53% | -11.28% | -14.81% | -10.88% | -1.90% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -4.93% | -8.76% | -4.64% | -2.17% | 7.67% |
| Operating Income | 4.93% | 8.53% | 4.41% | 1.92% | -8.49% |
| Income Before Tax | 3.57% | 10.43% | 3.42% | 1.78% | -8.86% |
| Income Tax Expenses | 648.36% | 576.92% | -67.39% | -54.47% | -23.54% |
| Earnings from Continuing Operations | 1.03% | 8.34% | 3.83% | 2.08% | -8.68% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 1.03% | 8.34% | 3.83% | 2.08% | -8.68% |
| EBIT | 4.93% | 8.53% | 4.41% | 1.92% | -8.49% |
| EBITDA | 4.94% | 8.54% | 4.44% | 1.95% | -8.44% |
| EPS Basic | 42.04% | 45.18% | 37.73% | 27.07% | 6.45% |
| Normalized Basic EPS | 43.28% | 46.14% | 37.46% | 26.86% | 6.27% |
| EPS Diluted | 42.04% | 45.18% | 37.73% | 27.07% | 6.45% |
| Normalized Diluted EPS | 43.28% | 46.14% | 37.46% | 26.86% | 6.27% |
| Average Basic Shares Outstanding | 75.84% | 75.68% | 61.01% | 34.99% | 22.07% |
| Average Diluted Shares Outstanding | 75.84% | 75.68% | 61.01% | 34.99% | 22.07% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |